ARCA Biopharma

ARCA aims to boost participation by easing stringent enrollment criteria in a study investigating Gencaro in heart failure patients with a favorable response genotype.

NEW YORK (GenomeWeb News) – Arca biopharma today said that Laboratory Corporation of America has told it that the US Food and Drug Administration has accepted LabCorp's investigational device exemption application for a companion diagnostic test for an atrial fibrillation drug under development.

Diaceutics, CAHG Launch Personalized Rx-Focused Marketing, Educational Firm Bioceutics

NEW YORK (GenomeWeb News) – Genome Diagnostics (GenDx) announced this week the launch of KimerDx, a spinout of GenDx focused on developing solid organ transplant tests for monitoring disease relapse and transplant rejection. The new firm is led by Doug Bost as managing director.

ARCA Biopharma, a firm developing genetically targeted treatments for cardiovascular diseases, has appointed Ray Woosley to its board of directors.

Response Genetics, Taiho Extend MDx Services Pact
Response Genetics could receive up to $950,000 for molecular diagnostic testing services provided to Taiho Pharmaceutical related to the development of cancer treatments.

The FDA has approved a trial investigating bucindolol in approximately 3,200 chronic heart failure patients who have a genotype associated with response to the beta-blocker and mild vasodilator.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.